EMA Authorised: Awiqli (insulin icodec) — Novo Nordisk A/S

View source ↗

Summary

EMA authorised Awiqli (insulin icodec) from Novo Nordisk A/S for the treatment of diabetes, including type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• AWIQLI (INSULIN ICODEC-ABAE)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus;Diabetes Mellitus, Type 2. MAH: Novo Nordisk A/S. Decision date: 02/10/2025